Arcus Biosciences, Inc. (RCUS) Stock
RCUS has an Alpha Score of 10 out of 100 (poor), computed on Nov 9, 2026 from 2 of 4 sub-scores. 5 of the hedge funds AlphaScala tracks reported RCUS in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $96.65M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Nov 10, 2026.
What is RCUS's Alpha Score?
How it works →Alpha Score of 10 reflects poor overall profile with poor momentum, poor quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 9, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own RCUS?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 3.14M | $96.65M | +136% |
| Marshall Wace | 1.95M | $59.97M | -48% |
| Millennium Management Israel Englander | 133K | $4.10M | NEW |
| D.E. Shaw David Shaw | 96K | $2.97M | -63% |
| Blackstone | 18K | $546.2K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Arcus Biosciences, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 21, 26 | Azoy Alexander | Chief Accounting Officer | SELL | 2.8K | $85K |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →What are RCUS's key statistics?
Key statistics as of Nov 10, 2026
How does RCUS's valuation compare with the Healthcare sector?
| Metric | RCUS | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -393.16% | 3.60% | 175 |
| Return on equity | -89.54% | 2.93% | 201 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 11, 2026). P/E excludes loss-making companies.
RCUS price chart
Powered by TradingViewWhat does Arcus Biosciences, Inc. do?
Arcus Biosciences Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. Focusing primarily on immuno-oncology, the company aims to harness the body's own immune system to target and eliminate cancer cells. Arcus Biosciences' pipeline includes a variety of monoclonal antibodies, small molecules, and combination therapies that address different aspects of cancer's complex biology. One of its core strategies is to develop next-generation treatments that can potentially improve upon existing therapies, enhancing efficacy while minimizing side effects. Operating in an industry marked by rapid scientific advancements, Arcus Biosciences plays a critical role in the ongoing pursuit of more effective cancer treatments. Its efforts contribute to the diversification of therapeutic options available to clinicians, offering hope to patients managing the challenges of cancer. Through strategic partnerships and robust research initiatives, Arcus Biosciences continues to expand its impact within the highly competitive biopharmaceutical sector, underscoring the importance of innovation in the battle against cancer.